Early in the COVID-19 pandemic, primary care doctors (general practitioners) and nurses had many questions. Cochrane Belgium wanted to create clear answers to primary care clinicians’ most frequent questions about COVID-19, based on scientific evidence, making the answers relevant to Belgium.
A university collected questions that were relevant to primary care in Belgium. Masters students studying medicine worked in pairs to draft answers in the Dutch language. Cochrane Belgium checked and validated each of these rapid answers to make sure they were accurate, consistent and evidence-based. They also developed criteria to assess each of the answers.
Author interview: the role of cognitive behavioural therapy for anxiety disorders in children and adolescents
In this short interview, Postdoctoral Researcher and lead author Tessa Reardon tells us about this recently published review.
What does this Cochrane review tell us about the role of cognitive behavioural therapy for anxiety disorders in children and adolescents?
Our review shows the key role cognitive behaviour therapy (CBT) plays in the treatment of anxiety disorders in children and adolescents. CBT is the most frequently evaluated treatment for these disorders. Indeed, this review includes 88 studies which is more than twice as many studies as the previous Cochrane review on this topic. Encouragingly, our findings reinforce previous conclusions that CBT is more effective than no treatment for anxiety disorders in children and adolescents. We didn’t find evidence that CBT is superior to alternative treatments, but few studies have compared CBT to alternative treatments so we are still not sure about this. The review also tells us most about the short-term benefits of CBT, and we still know relatively little about the extent to which these benefits continue in the medium to longer term.
What can CBT practitioners take from this evidence?
CBT practitioners can be reassured by the evidence of an advantage of CBT compared to waiting lists and no treatment. CBT can be provided in a range of different ways, for example, practitioners can work one-to-one with children, deliver group sessions, work with parents, deliver brief or longer treatments. Importantly, we did not find clear evidence that one way of providing CBT is more effective than another. A particular challenge facing practitioners and services is the very limited access to CBT for children and adolescents with anxiety disorders, and our findings suggest that practitioners can deliver relatively brief CBT interventions, without a negative impact on short-term outcomes.
Nevertheless, CBT practitioners cannot be complacent. This review suggests that about half of children and adolescents will recover from their primary anxiety disorder following a CBT intervention and this means that the other half do not recover. As researchers, we now need to focus on identifying how we can improve these recovery rates and what these children and young people who do not benefit from current CBT interventions need.
What can parents/carers of children and adolescents with anxiety disorders learn from this review?
Parents and carers can also be reassured that lots of studies have now evaluated CBT, and this review shows that CBT works well for many children and young people with anxiety disorders. However, it is equally important that parents and carers are aware that not all children and adolescents benefit from CBT, and some may need alternative support.
The extent to which parents are involved in CBT programmes for children and adolescents varies considerably – from little to no involvement, through to parent-led approaches where therapists support parents to apply CBT skills and strategies in their child’s daily life. We did not find evidence that one way of providing CBT is consistently better than another, but, not surprisingly, the parent-led approach has typically been tested with primary and preschool aged children, rather than teenagers.
The global pandemic has bought about concerns about increasing anxiety among children and adolescents - what can this review tell us about the role of CBT as treatment during this time?
Before the pandemic, anxiety disorders were common among children and adolescents, with concerns about increasing prevalence rates, particularly among adolescents. The pandemic has increased these concerns even further. Before the pandemic, we also knew that only a small minority of children and adolescents with anxiety disorders were accessing CBT, and the pandemic will have meant that even fewer children who may benefit from CBT are receiving it. Maximising the efficiency of CBT delivery is more important than ever to help ensure that children and adolescents can access effective treatment when they need it. Reducing the amount of therapist contact time involved in treatment and online delivery are both ways to potentially improve treatment efficiency. Encouragingly, this review indicates that CBT involving less than 10 hours of clinical contact can achieve similar outcomes to much longer treatments. Online delivery was beyond the scope of this review, but there is growing evidence that online CBT is also effective for children and adolescents with anxiety disorders.
It is with the deepest disappointment that we must confirm that as a result of the continued global spread and impact of COVID-19 (Coronavirus), we have taken the decision to cancel the Global Evidence Summit (GES 2), due to be hosted in Prague between 5-8 October 2021.
The Global Organizing Committee (comprising four partners: Cochrane, JBI, GIN and Campbell) concluded, with the agreement of our local host - CEBHC-KT and Masaryk University, that the most appropriate decision is to cancel the Summit in Prague in its entirety for 2021 and postpone it until 2 – 6 October 2023.
As global leaders in evidence-informed healthcare, the partners take very seriously our responsibility and duty of care to our communities in the face of continuing risks associated with the spread of the coronavirus for the foreseeable future.
However, we are committed to working together, along with additional organizations to present the second annual World EBHC Day on the 20 October, 2021. This is a global initiative that raises awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. The inaugural World EBHC Day that took place on 20 October 2020 was a great success. The intention for 2021 is to build on this year’s work and continue to celebrate the impact of individuals and organizations worldwide, recognizing the work of dedicated researchers, policymakers and health professionals in improving health outcomes.
Thursday, November 26, 2020
The cancellation of the second Global Evidence Summit is extremely disappointing news for all of us and we would like to thank the huge amount of people, including our local hosts, who have been working so hard on the preparations. We are in no doubt that we will be able to build successfully on the work accomplished so far to ensure that when GES 2 does go ahead in October 2023 in Prague it will be everything we anticipated: a world-class scientific event and a memorable gathering of the evidence-based medicine community in the historical capital of Bohemia.
We thank you for your ongoing support and commitment to the Global Evidence Summit and will look forward to meeting again for this unique event in 2023.
We hope that you all remain safe and well during these extraordinary times.
With our very best wishes,
Director, CEBHC-KT (Czech Cochrane, JBI and GRADE centres), Chair of the GES Scientific Committee and Local Organizing Committee
Executive Director, Joanna Briggs Institute
CEO, Guidelines International Network
CEO, The Campbell Collaboration
Cochrane Library Editor in Chief to present at Brigham and Women's Hospital Surgical Grand Rounds on 2 December
Dr. Karla Soares-Weiser, Editor in Chief of the Cochrane Library, will present at Brigham and Women's Hospital Surgical Grand Rounds on December 2, 2020, as part of the Professional Fulfillment Virtual Series. In the presentation, titled "Leadership, systematic reviews, and COVID: An international perspective", Dr. Soares-Weiser will reflect on her professional trajectory, Cochrane and its mission, and how Cochrane has confronted the COVID-19 pandemic.
All are welcome to join this presentation on December 2, 2020 from 8:15-9:15 am EST (check the time in your time zone). Please click the following link to access the Grand Rounds webinar: https://partners.zoom.us/j/81328907313Thursday, November 26, 2020
On 26th November 2020, the World Health Organization (WHO) launched their guidelines on physical activity and sedentary behaviour. This Special Collection curated by the Cochrane Campbell Global Ageing Partnership includes associated relevant topics addressing healthy ageing, aligning with the concerted global action of the Decade of Healthy Ageing (2020 to 2030). The WHO defines healthy ageing as “the process of developing and maintaining the functional ability that enables wellbeing in older age”. Functional ability includes people meeting their basic needs, being mobile, continuously learning and growing, building and maintaining relationships, and participating in society.
Older age can be accompanied by a greater risk of developing chronic non-communicable diseases, and associated functional limitations. People aged 60 years old and over account for nearly 25% of the disease burden arising from these conditions. However, being free of disease or health conditions is not a requirement for healthy ageing and many older adults have health conditions that can be well managed and therefore have little impact on their quality of life.
Physical activity plays a critical role in promoting healthy ageing, and evidence from epidemiological studies has determined that it is strongly associated with healthier ageing. Regular and adequate levels of physical activity have multiple health and wellbeing benefits and can prevent, or even reverse, some effects of chronic conditions across a lifespan. Popular ways to be active are through walking, cycling, dancing, and engaging in hobbies. Any other physical activity that is performed during leisure time, or during work, can have also have health benefits.
This years’ United Nations International Day of Older Persons focused on how the COVID-19 pandemic affects how ageing is addressed. The impact of quarantine, often in isolation, at home will have a substantial deconditioning effect, affecting millions of older people. Physical inactivity has been shown to be associated with noncommunicable diseases and higher mortality, and activity is now more important than ever, given COVID-19 restrictions.
This Special Collection brings together a selection of Cochrane Reviews assessing the benefits of physical activity interventions on activity levels, physical function, and symptoms. The reviews synthesize evidence regarding the general population, or groups of people who have specific health conditions. A future Special Collection will focus on specific exercise interventions.
China was the first country to identify COVID-19, but people didn’t know much about the virus in the early stages of the pandemic. To address this need for information, Cochrane China used the mobile telephone social media app WeChat to find out what doctors, nurses and members of the public wanted to know about COVID-19 and to share evidence with them.
Specifically, Cochrane China used WeChat to: advertise a survey to find out what doctors and nurses wanted to know about preventing and treating COVID-19, to invite volunteers to help them find evidence and translate it, and to keep in touch with people who were interested in their ongoing work.
- Learn more about what Cochrane China achieved by harnessing the power of social media during a pandemic, and what they learned in the process in this short case study.
Cochrane First Aid vs COVID-19: Making sure COVID-19 evidence is available in people’s preferred language
Cochrane published a rapid review about whether cleaning hands with ash reduces the spread of COVID-19 and other infectious diseases in areas where soap is not widely available. It was important to get this evidence out widely, so Cochrane First Aid translated the rapid review findings into six languages.
Cochrane First Aid worked with volunteers, and partnered with a number of organizations, to help to share evidence about handwashing with ash with lay people who educate the public in low-income countries. They also created a Blogshot (short visual summary) and used social media and their newsletter to share this review with a wide audience.
- Learn more about how Cochrane First Aid made sure this evidence was available to people in their preferred language in this short case study.
Stroke is a leading cause of death and disability worldwide. The chances of having a stroke increase with age and older people also appear to suffer greater consequences from COVID-19. There may be a link between COVID-19 and new strokes, so healthcare professionals may be caring for people who have both COVID-19 and stroke.
Cochrane Stroke heard from stroke care professionals and researchers that it was difficult to find relevant material amongst the thousands of articles available. To address this need, they collated useful resources for stroke care teams on their website. In addition, they made it easier for people to find relevant publications themselves by creating search strategies for stroke and Covid-19 for major databases including Google, MEDLINE, Pubmed, ClinicalTrials.gov, and The Cochrane Library.
- Learn more about how Cochrane Stroke approached this challenge, and what they learned in the process in this short case story.
Cochrane provides high-quality, relevant and up-to-date synthesized research evidence to inform health decisions. This page highlights the many ways that Cochrane has successfully responded to COVID-19 around the world. Click on any of the case studies below to find out more, and check back often as we continuously add and update new stories.
Making COVID-19 evidence easier to find - Cochrane Stroke heard from stroke care professionals and researchers that it was difficult to find relevant material amongst the thousands of articles available. Learn how Cochrane Stroke addressed this challenge.
Making sure COVID-19 evidence is available in people’s preferred language - Cochrane published a rapid review about whether cleaning hands with ash reduces the spread of COVID-19 and other infectious diseases in areas where soap is not widely available. Read how Cochrane First Aid made sure this evidence was available to people in their preferred language.
Shaping and sharing COVID-19 evidence with social media - Cochrane China used the mobile telephone social media app WeChat to find out what doctors, nurses and members of the public wanted to know about COVID-19 and to share evidence with them. Learn more about what Cochrane China achieved by harnessing the power of social media during a pandemic.
Tuesday, November 24, 2020 Category: The difference we make
What are routine laboratory tests?
Routine laboratory tests are blood tests that assess the health status of a patient. Tests include counts of different types of white blood cells (these help the body fight infection), and detection of markers (proteins) that indicate organ damage, and general inflammation. These tests are widely available and in some places they may be the only tests available for diagnosis of COVID-19.
What did the authors want to find out?
People with suspected COVID-19 need to know quickly whether they are infected so that they can self-isolate, receive treatment, and inform close contacts.
Currently, the standard test for COVID-19 is usually the RT-PCR test. In the RT-PCR, samples from the nose and throat are sent away for testing, usually to a large, central laboratory with specialist equipment. Other tests include imaging tests, like X-rays, which also require specialist equipment.
The authors of this review wanted to know whether routine laboratory tests were sufficiently accurate to diagnose COVID-19 in people with suspected COVID-19. They also wanted to know whether they were accurate enough to prioritize patients for different levels of treatment.
What did the author team do?
Authors searched for studies that assessed the accuracy of routine laboratory tests to diagnose COVID-19 compared with RT-PCR or other tests. Studies could be of any design and be set anywhere in the world. Studies could include participants of any age or sex, with suspected COVID-19, or use samples from people known to have – or not to have - COVID-19.
What authors found
The authors found 21 studies that looked at 67 different routine laboratory tests for COVID-19. Most of the studies looked at how accurately these tests diagnosed infection with the virus causing COVID-19. Four studies included both children and adults, 16 included only adults and one study only children. Seventeen studies were done in China, and one each in Iran, Italy, Taiwan and the USA. All studies took place in hospitals, except one that used samples from a database. Most studies used RT-PCR to confirm COVID-19 diagnosis.
Accuracy of tests is most often reported using ‘sensitivity’ and ‘specificity’. Sensitivity is the proportion of people with COVID-19 correctly detected by the test; specificity is the proportion of people without COVID-19 who are correctly identified by the test. The nearer sensitivity and specificity are to 100%, the better the test. A test to prioritize people for treatment would require a high sensitivity of more than 80%.
Where four or more studies evaluated a particular test, the authors of this review pooled their results and analyzed them together. Their analyses showed that only three of the tests had both sensitivity and specificity over 50%. Two of these were markers for general inflammation (increases in interleukin-6 and C-reactive protein). The third was for lymphocyte count decrease. Lymphocytes are a type of white blood cell where a low count might indicate infection.
How reliable are the results?
Confidence in the evidence from this review is low because the studies were different from each other, which made them difficult to compare. For example, some included very sick people, while some included people with hardly any COVID-19 symptoms. Also, the diagnosis of COVID-19 was confirmed in different ways: RT-PCR was sometimes used in combination with other tests.
How up-to-date is this review?
The authors searched all COVID-19 studies up to 4 May 2020.
Who do the results of this review apply to?
Routine laboratory tests can be issued by most healthcare facilities. However, these results are probably not representative of most clinical situations in which these tests are being used. Most studies included very sick people with high rates of COVID-19 virus infection of between 27% and 76%. In most primary healthcare facilities, this percentage will be lower.
What does this mean?
Routine laboratory tests cannot distinguish between COVID-19 and other diseases as the cause of infection, inflammation or tissue damage. None of the tests performed well enough to be a standalone diagnostic test for COVID-19 nor to prioritize patients for treatment. They will mainly be used to provide an overall picture about the health status of the patient. The final COVID-19 diagnosis has to be made based on other tests.
Implications for practice
None of these markers as stand‐alone tests are useful for accurately ruling in or ruling out COVID‐19. As a triage test would require a high sensitivity (< 80%), these tests have limited value as triage tests. Although there is low or very low certainty about the summary estimates in this review, we do not expect that studies with a low risk of bias will show a better performance than the tests included.
Implications for research
Future studies focusing on the usefulness of routine laboratory tests for COVID‐19 may consider a more representative sample of the population, focus on markers with prespecified, clinically sound cut‐offs and focus on single, but also on the combination of regular blood markers. Furthermore, considering the test results as continuous values may be more informative, as larger deviations from the reference values will have greater impact on the health status of the tested people, and might enable more personalized treatment.
In 2016, Cochrane Pregnancy and Childbirth published a systematic review looking at if skin-to-skin contact improved breastfeeding rates and helped babies adjust to the outside world. They looked at the results of 46 studies which included almost 4000 mothers and their babies. Overall, their review supports the use of skin-to-skin to encourage breastfeeding. The evidence suggests that early skin-to-skin should be normal practice for healthy newborns including those born by caesarean and babies born early at 35 weeks or more. Even where skin-to-skin is possible only for a short time, it will still encourage successful breastfeeding one to four months post birth. Importantly, the findings of improved breastfeeding rates were found in diverse countries and among women of low and high socio-economic class.
Since publication, this review has informed 20 sets of guidelines around the world, with the World Health Organisation (WHO) referencing the review in their 2017 guidance for promoting and supporting breastfeeding. It has been translated into five languages.
Elizabeth Moore, Associate Professor of Nursing at Vanderbilt University School of Nursing and lead author of the review said:
"I have really been amazed at the impact that this Cochrane Review has had around the world. It started as just a gut feeling I had as a breastfeeding consultant over 20 years ago that placing mothers and babies together skin-to-skin right after birth would help them breastfeed more successfully. Since then, this profound, but simple intervention has spread throughout the world based on the evidence in this review.”
In the UK, NICE has used the evidence in their 2006 guidance, and the latest revision in 2015, with the recommendation that women have skin-to-skin contact with their babies after birth. The Royal College of Nursing, UNICEF and Public Health England have all cited the research to promote skin-to-skin contact after birth. As a result, a 2019 survey by the Care Quality Commission reported that 93% of women in England had skin-skin contact after birth.
In June 2020, the WHO stated that skin-to-skin contact and breastfeeding should still be encouraged for new mothers and their babies in cases of suspected or confirmed COVID-19. Early evidence suggests that the benefits of skin-to-skin and breastfeeding far outweigh any risks.
- Read the full Cochrane Review: Early skin‐to‐skin contact for mothers and their healthy newborn infants
- Read the Plain Language summary in English, Deutsch, Español, Français, Hrvatski, 日本語, 한국어, Bahasa Malaysia, Português, Русский, ภาษาไทย, and 繁體中文
- Visit the Cochrane Pregnancy and Childbirth Website
- Listen to the lead author explain the results
- Read 'Case study: Skin-to-skin contact to encourage breastfeeding' on NIHR
Why is this question important?
Basal cell carcinoma (BCC) is the most common form of skin cancer among people with white skin.
BCC is not usually life‐threatening but if left untreated, it can cause important disfigurement, especially on the face.
Surgical removal of the affected area and surrounding skin is usually the first option for treating BCC. Several different surgical approaches exist as well as non‐surgical treatments, such as radiotherapy (high doses of radiation that kill cancer cells), and anti‐cancer creams, gels and ointments.
We reviewed the evidence from research studies, to find out which treatments work best for BCC.
How did we identify and evaluate the evidence?
We searched for randomised controlled studies (studies where people are randomly put into one of two or more treatment groups), because these provide the most robust evidence about the effects of a treatment. We compared and summarised the evidence from all the studies. Finally, we rated our confidence in the evidence, based on factors such as study methods and sizes, and the consistency of findings across studies.
What did we find?
We found 52 studies that involved a total of 6690 adults with BCC. Most studies (48 out of 52) included hospital outpatients with small, superficial or nodular BCC. Studies lasted for between six weeks and 10 years (average duration: 13 months). Twenty‐two studies were funded by pharmaceutical companies.
Our confidence in the evidence presented here is low to moderate, mainly because many studies were small.
Comparison between different surgical treatments
- Mohs micrographic surgery (a specialised surgical approach that removes less skin) may slightly decrease recurrence rates at three and five years compared to surgical excision (one of the most common surgical treatments for BCC).
- There may be little to no difference in how well scars heal between these two surgical treatments according to patients and observers (one study).
Surgery versus non‐surgical treatments
Compared against surgical excision:
- Imiquimod (an anti‐cancer cream) probably increases BCC recurrence rates at three and five years. There may be little to no difference in scar healing according to patients, although imiquimod may increase chances of scars healing well when healing is rated by an observer (one study).
- Radiotherapy may increase BCC recurrence rates at three and four years, and probably decreases chances of scars healing well (one study).
- MAL‐PDT, a type of photodynamic therapy (that uses a light source and light‐sensitive medicine to kill cancer cells), may increase BCC recurrence rates at three years. MAL‐PDT probably increases chances of scars healing well (two studies).
Comparison of different non‐surgical treatments
Compared against imiquimod:
- MAL‐PDT probably increases BCC recurrence rates at three and five years. There is probably little to no difference in scar healing (one study);
What does this mean?
Overall, the evidence suggests that:
- surgery could reduce chances of BCC recurrence;
- non‐surgical treatments such as anti‐cancer creams or photodynamic therapy carry an increased chance of BCC recurrence, but could increase chances of scars healing well compared with surgery.
Complications with surgical treatments include wound infections, skin graft failure and bleeding after the procedure. Non‐surgical treatments frequently lead to localised itching, weeping, pain and redness. Treatment‐related side effects that caused modifications to the study or the withdrawal of participants occurred with imiquimod and MAL‐PDT.
How‐up‐to date is this review?
The evidence in this Cochrane Review is current to November 2019
An updated Cochrane review published today in the Cochrane Library summarizes randomized trial evidence about face masks, hand washing and physical distancing to interrupt or reduce the spread of respiratory viruses. The review will inform revised guidance due to be released by the World Health Organisation.
Lisa Bero, Cochrane Public Health and Health Systems Senior Editor and an author on an Editorial published to accompany this review said, “The results of this review should be interpreted cautiously, and the uncertain findings should not be taken as evidence that these measures are not effective. Most of the trials looked at the effects of measures like face masks and hand washing on their own, however no single measure alone will be enough to reduce the spread of COVID-19. Public health decision makers need to consider all of the available evidence and are likely to act on uncertain evidence if the intervention has the potential to protect the health of large populations and it is unlikely to lead to very serious harm.”
What are respiratory viruses?
Respiratory viruses are viruses that infect the cells in your airways: nose, throat, and lungs. These infections can cause serious problems and affect normal breathing. They can cause flu (influenza), severe acute respiratory syndrome (SARS), and COVID-19.
How do respiratory viruses spread?
People infected with a respiratory virus spread virus particles into the air when they cough or sneeze. Other people become infected if they come into contact with these virus particles in the air or on surfaces on which they have landed. Respiratory viruses can spread quickly through a community, through populations and countries (causing epidemics), and around the world (causing pandemics).
How can we stop the spread of respiratory viruses?
Physical measures to try to stop respiratory viruses spreading between people include:
- washing hands often;
- not touching your eyes, nose, or mouth;
- sneezing or coughing into your elbow;
- wiping surfaces with disinfectant;
- wearing masks, eye protection, gloves, and protective gowns;
- avoiding contact with other people (isolation or quarantine);
- keeping a certain distance away from other people (distancing); and
- examining people entering a country for signs of infection (screening).
Why the authors did this Cochrane Review
The authors of this review wanted to find out whether physical measures stop or slow the spread of respiratory viruses.
What did authors do?
The authors searched for studies that looked at physical measures to stop people catching a respiratory virus infection.
They were interested in how many people in the studies caught a respiratory virus infection, and whether the physical measures had any unwanted effects.
Search date: This is an update of a review first published in 2007. We included evidence published up to 1 April 2020.
What the authors found
Review authors identified 67 relevant studies. They took place in low-, middle-, and high-income countries worldwide: in hospitals, schools, homes, offices, childcare centres, and communities during non-epidemic influenza periods, the global H1N1 influenza pandemic in 2009, and epidemic influenza seasons up to 2016. No studies were conducted during the COVID-19 pandemic. The authors identified six ongoing, unpublished studies; three of them evaluate masks in COVID-19.
One study looked at quarantine, and none eye protection, gowns and gloves, or screening people when they entered a country.
The authors assessed the effects of:
- medical or surgical masks;
- N95/P2 respirators (close-fitting masks that filter the air breathed in, more commonly used by healthcare workers than the general public); and
- hand hygiene (hand-washing and using hand sanitiser).
What are the results of the review?
Medical or surgical masks
Seven studies took place in the community, and two studies in healthcare workers. Compared with wearing no mask, wearing a mask may make little to no difference in how many people caught a flu-like illness (9 studies; 3507 people); and probably makes no difference in how many people have flu confirmed by a laboratory test (6 studies; 3005 people). Unwanted effects were rarely reported, but included discomfort.
Four studies were in healthcare workers, and one small study was in the community. Compared with wearing medical or surgical masks, wearing N95/P2 respirators probably makes little to no difference in how many people have confirmed flu (5 studies; 8407 people); and may make little to no difference in how many people catch a flu-like illness (5 studies; 8407 people) or respiratory illness (3 studies; 7799 people). Unwanted effects were not well reported; discomfort was mentioned.
Following a hand hygiene programme may reduce the number of people who catch a respiratory or flu-like illness, or have confirmed flu, compared with people not following such a programme (16 studies; 61,372 people). Few studies measured unwanted effects; skin irritation in people using hand sanitiser was mentioned.
How reliable are these results?
The authors' confidence in these results is generally low for the subjective outcomes related to respiratory illness, but moderate for the more precisely defined laboratory-confirmed respiratory virus infection, related to masks and N95/P2 respirators. The results might change when further evidence becomes available. Relatively low numbers of people followed the guidance about wearing masks or about hand hygiene, which may have affected the results of the studies.
We are uncertain whether wearing masks or N95/P2 respirators helps to slow the spread of respiratory viruses.
Hand hygiene programmes may help to slow the spread of respiratory viruses.
Reducing the transmission of Coronavirus disease 2019 (COVID-19) is a global priority. Toward this end, public health officials and politicians across the world have been seeking scientific expertise to guide policy. In response, investigators have rushed to share new results on preprint servers, and journals have expedited editorial and peer review processes to publish them. The urgency to define the relevant knowledge base in preventing, diagnosing, and managing COVID-19 infection and its sequelae has required intense collaboration in evidence generation and synthesis, in order to provide public health officials with authoritative guidance.
A newly published Cochrane Library Editorial addresses how Cochrane has responded to the COVID-19 pandemic, what the limitations to COVID-19 evidence are, and suggestions on how policy makers can move forward with best available evidence. This Editorial publishes alongside the updated Cochrane Review 'Physical interventions to interrupt or reduce the spread of respiratory viruses'.
Why is this review important?
Many children and young people experience problems with anxiety. Children and young people with anxiety disorders are more likely than their peers to have difficulty with friendships, family life, and school, and to develop mental health problems later in life. Therapies such as cognitive behavioural therapy (CBT) can help children and young people to overcome difficulties with anxiety by using new ways of thinking and facing their fears.
Who will be interested in this review?
Parents, children, and young people; people working in education and mental health services for children and young people; and general practitioners.
What questions does this review aim to answer?
This review updates and replaces previous Cochrane Reviews from 2005 and 2015, which showed that CBT is an effective treatment for children and young people with anxiety disorders.
This review aimed to answer the following questions:
- Is CBT more effective than a waiting list or no treatment?
- Is CBT more effective than other treatments and medication?
- Does CBT help to reduce anxiety for children and young people in the longer term?
- Are some types of CBT more effective than others? (e.g. individual versus group therapy)
- Is CBT effective for specific groups? (e.g. children with autism)
Which studies were included in the review?
We searched the databases to find all studies of CBT for anxiety disorders in children and young people published up to October 2019. In order to be included in the review, studies had to be randomised controlled trials (a type of study in which participants are assigned to one of two or more treatment groups using a random method) and had to include young people under 19 years of age with an anxiety disorder diagnosis. We included 87 studies with a total of 5964 participants in the analysis.
What does the evidence from the review tell us?
We rated the overall quality of the evidence as 'moderate’ or 'low'. There is evidence that CBT is more effective than a waiting list or no treatment in reducing anxiety in children and young people, although the findings did vary across studies. There is no clear evidence that CBT is more effective than other treatments. A small number of studies looked at outcomes six months after CBT was given and showed that reductions in anxiety continued. We found no clear evidence that one way of providing CBT is more effective than another (e.g. in a group, longer treatments, with parents) or that CBT is more or less effective for any specific group of children (e.g. children with autism spectrum disorders).
What should happen next?
Future research should compare CBT to alternative treatments and medication; identify who does and does not benefit from CBT and what those who do not benefit need; establish how to make CBT more accessible; and give far more consideration to neglected populations, including children and young people from low‐ and middle‐income countries.
Following a session in May, a resumed World Health Assembly is taking place virtually this week (9-14 November).
The World Health Assembly (WHA) is the decision-making body of the World Health Organization (WHO) and is attended by representatives of all Member States.
Our statement pledges support for the Decade of Healthy Ageing and highlights some of the work that the Cochrane Campbell Global Ageing Partnership is undertaking to help strengthen the evidence base in this area.
The full statement is below:
COVID-19 has emphasized the critical importance of evidence-informed global health policy. Governments, healthcare professionals and researchers worldwide continue to seek answers to questions related to the treatment of patients, and how best to protect populations. The pandemic has disproportionately affected older people and has demonstrated the need for and importance of good quality data and evidence to support them.
Cochrane is a global leader in producing high-quality synthesized evidence to inform health decision making. We are working closely with WHO in response to the pandemic by producing rapid reviews and living systematic reviews to answer COVID-19-related priority questions, as well as launching and maintaining one of the largest and most sophisticated registries of COVID-19 studies and a living synthesis of COVID-19 study results. In the area of ageing, the Cochrane Campbell Global Ageing Partnership produces and widely disseminates high-quality, high-priority systematic reviews of all available evidence, identifies evidence gaps and develops methods for evidence synthesis related to ageing. These syntheses will enable informed decision-making and policy development aimed at improving the lives of older people, their families and communities. The impacts of the pandemic clearly show that this work is more crucial now than ever.
The Cochrane Campbell Global Ageing Partnership pledges its commitment to the Decade of Healthy Ageing. We are working with the WHO Ageing and Health team and as members of the International Consortium on Evidence and Metrics for Healthy Ageing. This consortium is playing a key role in strengthening data, research and innovation, generating impact for older people’s health and wellbeing. There are still major evidence gaps and the Decade of Healthy Ageing will allow us to focus on research and innovation for improving the lives and wellbeing of older people.
Rapid research requires teamwork and methodological expertise – Cochrane praised in recent publication
‘A QuESt for speed: rapid qualitative evidence syntheses as a response to the COVID-19 pandemic’ published in BMC Systematic Review
In a recently published article, the research team of a Cochrane rapid qualitative evidence synthesis reflects on their experience and discuss the challenges they were faced with at each stage of the review. The authors describe practical considerations and stress the level of methodological expertise and dedication needed to deliver a qualitative evidence synthesis rapidly and accurately during the COVID-19 pandemic.
Throughout the paper, the team praise the collaborative nature of Cochrane and its importance when working to extreme deadlines in a pandemic situation, as in the excepts below:
"…We highlight the broader team of supporters, including the editors, peer reviewers, translators, healthcare workers, end-user stakeholders, and the broader Cochrane community. The membership of our immediate team and the support we received from the wider community was critical in completing and publishing our review within this timeframe. The core team had worked together previously and this also enhanced our completion trajectory. The merits of conducting rapid research with people who recognise each other’s work ethic, skill sets and personalities receive almost no attention in the literature...
The generosity of everyone to answer this question played a role that cannot be underestimated. In addition, through the Cochrane structure, the team had access to an international network offering specialised methodological and practical support. Cochrane EPOC’s editorial team maintains high levels of QES expertise providing essential guidance for sections of the review, as well as experience in dissemination and end-user input. The Cochrane community was quickly able to identify peer reviewers and copy editors, who contributed within the timeline…."
Kayleigh Kew, Cochrane’s Senior Editor for Methods commented: “The rapid qualitative evidence synthesis described is a true success story. The quality achieved in COVID-19 rapid reviews with such an unforgiving timelines show what is possible when dedicated authors come together with Cochrane’s vast and experienced network of editors and experts. Reflections from Cochrane authors and contributors like those presented in this article help the organization to learn from what has been achieved to continue producing high-quality, relevant syntheses when they are needed most.”
In 2020, people aged 60 years or over outnumber children under 5 years, for the first time in history; and by 2050, it is estimated that there will be more than twice as many people over 60 as children under 5, and outnumber adolescents and young people aged 15–24 years. To mark this change in our global population The World Health Organisation (WHO) Decade of Healthy Ageing has been established.
The WHO defines Healthy Ageing as ‘the process of developing and maintaining the functional ability that enables wellbeing in older age’ and includes creating environments and opportunities for people to be and do what they value for the extent of their lives.
The Cochrane Campbell Global Ageing Partnership has worked with the WHO since 2015, and aims to promote the dissemination, accessibility, and impact of Cochrane and Campbell Reviews, while increasing their applicability to address the health care priorities and wellbeing of older people globally. The Partnership also recognizes a need for producing and disseminating evidence to drive research to address the healthcare, social needs and inequalities of an increasingly older population. Reviews need to reflect the multidisciplinary nature of ageing in order to be relevant and accessible to a wide audience of policymakers, educators, commissioners, funders, and consumers. This decade will highlight and support this work for both Cochrane and the WHO.
Tracey Howe, who is leading this project within Cochrane said,
“This is an opportunity for us to inform and help the WHO when it comes to advice about healthy ageing. We are delighted to partner on this important initiative and focus on having a global impact. Our work will prioritise the major causes of disability affected life years, called DALYS, for people over 50 including cardiovascular disease, stroke, COPD, cancer, Alzheimer’s disease, dementias, diabetes and falls looking at how Cochrane can play it’s part in improving the evidence, and access to this evidence, on these globally important health topics.”Related work
- Read about the WHO Decade of Global Ageing
- Visit The Cochrane Campbell Global Ageing Partnership website
- Cochrane statement to the 73rd World Health Assembly about the Decade of Healthy Ageing
- Prof Tracey Howe appears in Decade of Healthy Ageing ‘Leaders Voices’ video alongside WHO and UN leadership
The Association for Healthcare Social Media (AHSM) is a professional society devoted to the use of social media by healthcare professionals. The multispecialty and multidisciplinary AHSM assists health professionals in utilizing social media platforms to serve as disseminators of accurate health information while doing so responsibly. AHSM members include many of the virtual physicians and nurses of TikTok, Instagram, Twitter, and YouTube who are disseminating important healthcare-related information to their audiences.
We spoke with Austin Chiang, MD, MPH, a founding member of the AHSM and the chief medical social media officer at Jefferson Health, in Philadelphia about AHSM and the role of social media is playing in disseminating health information.
Hi Dr. Chiang, would you mind telling us a bit more about yourself?
Sure! I am a gastroenterology and advanced/bariatric endoscopist by training and currently am an assistant professor of medicine, director of the endoscopic bariatric program, and chief medical social media officer at Jefferson Health in Philadelphia. I completed my undergraduate studies at Duke University, medical school at Columbia University, and internal medicine residency at Columbia, New York Presbyterian Hospital, as well. Thereafter, my gastroenterology and bariatric endoscopy training was completed at Brigham and Women's Hospital, and I received a master's in public health at the Harvard TH Chan School of Public Health. My final fellowship was completed at Jefferson, where I stayed on as faculty.
You sound busy! And you are a founding members of AHSM - how did that get started?
Well, after years of being on social media, many of my colleagues, mainly physicians on Instagram, started noticing concerning trends of people misrepresenting themselves as a health experts without the requisite training. This led to the #verifyhealthcare hashtag campaign, that brought the founders together and led us to consider many other concerning observations we had of health professionals on social media. We were also eager to share with other health professionals how many of us had managed to reach larger audiences by using social media productively.
What does AHSM do?
While many of us are driven by our desire to put forth accurate health information on social media, we are most passionate about helping health professionals use social media effectively and responsibly to meet patients where they are. Without an increased professional presence on social media, misinformation can be easily perpetuated and audiences misled. However, getting health professionals online also requires guidance and incentives. Social media is rapidly evolving and can be time consuming. We therefore felt the need to create a 501(c)(3) professional society to help legitimize social media in health and collaborate with institutions and organizations. In our inaugural year we held a two-day conference, had a co-branded course with YouTube about how to optimize one's experience on the platform, and worked with Cochrane on World Evidence-Based Healthcare Day!
You have 55.4K followers on Instagram and 316.3K on TicTok. But not everyone is convinced that social media is a great way to disseminate health evidence because it’s a ‘serious and complex’ topic. What do you think about this?
People of all age groups are spending more time than ever before on social media. The average time per day exceeds two hours per day on social media. Individuals and advertisers across sectors have capitalized on this usage to promote their services and products. Especially during the pandemic, there has been growing attention in health. Social media is not only a great way to distribute health knowledge, it is absolutely imperative in 2020. "Serious and complex" topics can impact everyone, and without trained individuals to interpret that information, medical misinformation could wreak havoc.
It's been helpful to get a bit of 'social media star' power behind Cochrane with your member's posts. How has it been working closely with Cochrane?
It's been great! Our AHSM members know Cochrane as the ‘gold standard’ in consolidating health evidence through systematic reviews and it's been exciting to share Cochrane evidence and evidence-based medicine principles directly with our lay audience. With the COVID-19 pandemic, everyone is looking for health information online. With additional time spent on social media channels, there is also greater exposure to misinformation and misrepresentation of evidence online. Our members are health professionals that are provided with the tools and training to share health evidence on social media and actively work towards fighting misinformation. The COVID-19 pandemic has underscored the importance of educating our audiences about evidence based healthcare and the high quality evidence that Cochrane provides.
What’s your advice to med students, clinicians and researchers, and scientists in healthcare that are thinking about using social media?
Take it a step at a time. It's ok to observe and reach out to people who you look up to for advice on social media. People who are active on social media are used to putting themselves out there and helping colleagues out. Also, think about your purpose and what you're hoping to achieve. This really dictates which platform is most suitable and what approach to take.
That's great advice. What do you think the benefits are to the creator and to the audience?
The benefits are numerous to both. For the creator, you access the latest information in real time, you build valuable networks, build practices, and participate in riveting conversations. For the audience it may be knowledge and access to health professionals you otherwise might not have had, and opportunities to learn about treatments and trials that would otherwise remain unknown.
We have an 'Early Career Professionals Cochrane Group' who have been especially keen on using social media. How do you think early career professionals can leverage social media?
It depends on how early is early. I think we all develop a different comfort level of when we decide we are "qualified" to educate and discuss about topics online. I think no matter what stage someone is at, there is value. Pre-med and medical students share important perspectives that can inspire those aspiring students behind them, while informing those more senior to them.
Thanks for speaking with us, Dr. Chiang!
If you would like to learn more about AHSM:
If you would like to learn more about social media at Cochrane:
- Free webinar: Leverage Social Media, 18 November
- Get social with Cochrane!
- Cochrane Training social media resources
Thursday, November 12, 2020
Prof Tracey Howe appears in Decade of Healthy Ageing ‘Leaders Voices’ video alongside WHO and UN leadership
Professor Tracey Howe, Director of the Cochrane-Campbell Global Ageing Partnership and Co-Chair of the Cochrane Governing Board, has pledged support for the Decade of Healthy Ageing (2020-2030) in a video alongside António Guterres, UN Secretary-General; Dr Tedros Adhanom Ghebreyesus, WHO Director-General; Professor Klaus Schwab, Founder and Executive Chairman of the World Economic Forum; Dr Natalia Kanem, Executive Director United Nations Population Fund; the International Federation on Ageing; and HelpAge International.
The Decade of Healthy Ageing aims to bring together governments, civil society, international agencies, professionals, academia, the media, and the private sector to jointly take action in order to improve the lives of older people, their families, and the communities in which they live.
The Cochrane-Campbell Global Ageing Partnership has been actively supporting WHO in preparing for the Decade of Healthy Ageing, which is expected to formally launch via the United Nations in the coming months. We look forward to sharing the outputs of this collaboration in due course.